Kidney

Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer

ANAHEIM, Calif.--(BUSINESS WIRE)--May 21, 2007 - Antigenics Inc.(NASDAQ: AGEN) today announced additional follow-up data on thecompany's Phase 3 investigational therapeutic cancer vaccineOncophage(R) (vitespen). The end-of-study results, which reflect anadditional 17 months' data collection, showed that in a substantialsubset of patients (n = 362) at intermediate risk for diseaserecurrence,...

Early Results of the CellCept Spare the Nephron Study Examine Kidney Function

SAN FRANCISCO, May 07, 2007 /PRNewswire/ -- Interim results froma multicenter trial investigating a novel kidney-sparing treatmentprotocol using CellCept(R) (mycophenolate mofetil) were presentedat the American Transplant Congress. This and other Spare theNephron (STN) trials in kidney and liver transplant recipientsexamine ways to prevent rejection without damaging kidneys. As tra...

Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial

EDMONTON, May 07, 2007 /PRNewswire-FirstCall/ - Isotechnika Inc.today announced the audited three month results, reviewed by theData Monitoring Committee, of the first third of the patientstreated in its Phase 2b de novo kidney transplant trial for theCompany's lead immunosuppressive drug, ISA247. This interim analysis is based upon the assessment of the first116 patients enrolled....

Mircera Effective in Stabilising Haemoglobin Levels in Elderly Patients With Kidney Disease on Dialysis

Findings Illustrate Role of Innovative New Treatment in PopulationMost Affected by Chronic Kidney Disease BASEL, Switzerland, April 23, 2007 /PRNewswire/ -- A new RochePhase III analysis shows once-monthly MIRCERA, a continuouserythropoietin receptor activator, effectively treats renal anaemiain one of the fastest growing groups of patients with chronickidney disease (CKD) -- elderly pati...

Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease

PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced results to date from two separatePhase 2 clinical trials of Hematide(TM) in dialysis andnon-dialysis chronic kidney disease (CKD) patients. The data showedthat in treatment naive, non-dialysis patients Hematide couldcorrect anemia when administered monthly at an appropriate dose.Similarly, the data...

Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease

CAMBRIDGE, Mass., April 16, 2007 /PRNewswire-FirstCall/ --Genzyme Corp. announced today that a recently completed study ofRenvela(TM) (sevelamer carbonate) achieved its primary endpoint,demonstrating a statistically significant reduction in serumphosphorus for hyperphosphatemic patients with chronic kidneydisease who are not on dialysis. Patients treated with Renvela also achieved...

Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease

ORLANDO, Fla. and NUTLEY, N.J., April 12, 2007/PRNewswire-FirstCall/ -- Data analyses from the largest initialregistration clinical trial program ever undertaken in the renalanemia arena provide efficacy and safety information on theinvestigational anemia therapy MIRCERA(TM) for the treatment ofrenal anemia associated with chronic kidney disease (CKD) inpatients on dialysis and not on di...

Isotechnika's independent data monitoring committee conducts review of phase 2b kidney transplant trial

- Company Set to Host Evening Symposium at ATC - EDMONTON, March 27 /CNW/ - Isotechnika Inc. announced today thatan independent data monitoring committee (DMC) has met and reviewedthe interim data from the Phase 2b kidney transplant (PROMISE)trial. The review included 3 month data from approximately 1/3 ofthe anticipated 332 patients to be enrolled. The DMC hasrecommended that...

Nearly 1 in 10 Americans Has A Relative With Kidney Failure

African-Americans with Family History of ESRD Are at HighRisk WASHINGTON, March 9, 2007 - Approximately ten percent of U.S.adults have a family history of end-stage renal disease (ESRD), andthese individuals appear to be at increased risk of developingkidney disease themselves, reports a study in the April Journal ofthe American Society of Nephrology. "A family histo...

Advanced Magnetics Announces Presentation of Ferumoxytol Data at the National Kidney Foundation 2007 Spring Clinical Meetings

CAMBRIDGE, Mass., March 06, 2007 /PRNewswire-FirstCall/ --Advanced Magnetics today announced that data from three completedPhase III multi- center clinical studies of ferumoxytol as anintravenous iron replacement therapeutic will be presented duringthe National Kidney Foundation (NKF) 2007 Spring Clinical Meetingstaking place April 10th through 14th in Orlando, Florida. Twoposters contai...